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review and meta-analysis
Yunus Arik1, Frans SS Leijten2, Tatjana Seute2, Pierre A Robe3 and Tom J Snijders2*Abstract
Background: Status epilepticus (SE) is a medical emergency with high mortality rates. Of all SE’s, 7% are caused by
a brain tumor. Clinical guidelines on the management of SE do not make a distinction between tumor-related SE
and SE due to other causes. However, pathophysiological research points towards specific mechanisms of epilepsy
in brain tumors. We investigated whether clinical features support a distinct profile of tumor-related SE by looking
at measures of severity and response to treatment.
Methods: Systematic review of the literature and meta-analysis of studies on adult SE that report separate data for
tumor-related SE and non-tumor-related SE on the following outcomes: short-term mortality, long-term morbidity,
duration of SE, and efficacy of anticonvulsant intervention.
Results: Fourteen studies on outcome of SE were included. Tumor-related SE was associated with higher mortality
than non-tumor-related SE (17.2% versus 11.2%, RR 1.53, 95%-CI 1.24-1.90). After exclusion of patients with
hypoxic-ischemic encephalopathy (a group with a known poor prognosis) from the non-tumor-group, the
difference in mortality increased (17.2% versus 6.6%; RR 2.78, 95%-CI 2.21 – 3.47). Regarding long-term morbidity
and duration of SE there were insufficient data. We did not find studies that systematically compared effects of
therapy for SE between tumor- and non-tumor-related SE.
Conclusions: Based on – mostly retrospective – available studies, short-term mortality seems higher in tumor-related
SE than in SE due to other causes. Further studies on the outcome and efficacy of different therapeutic regimens
in tumor-related SE are needed, to clarify whether tumor-related SE should be regarded as a distinct clinical entity.
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Epilepsy is very common in patients with brain tumors; de-
pending on the type of tumor, estimates of the frequency of
epilepsy vary between 10 and 100% [1]. While 30 to 50% of
the patients with a brain tumor present with seizures, 10 to
30% develop seizures in the course of the disease [2-5]. In
low-grade tumors, slow growth probably gives rise to the
development of focal or remote cell changes. These cell
changes are associated with epileptogenesis. Rapidly pro-
gressive tumors (high-grade lesions) are thought to induce
epilepsy through abrupt tissue damage [1].* Correspondence: T.J.Snijders@umcutrecht.nl
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unless otherwise stated.Continuous seizure activity of five minutes poses an
increased risk of status epilepticus (SE) [6]. Seven per-
cent of all adult SE are caused by a brain tumor [7]. In
most national and international guidelines, SE is consid-
ered a single clinical entity, although there is a consen-
sus that partial and non-convulsive forms of SE should
not be treated as aggressively as generalized convulsive
SE. In these types of SE, the risk of intensive sedative
treatment and intubation probably does not outweigh the
benefits of seizure control [8]. Most clinical guidelines on
the management of SE do not make a distinction between
tumor-related SE and SE due to other causes.
However, recent pathophysiological studies point towards
specific mechanisms of epilepsy in brain tumors. The
tumor is, through invasion and infiltration, responsible for. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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leading to changes in the peritumoral tissue. These changes
contribute to the imbalance of excitation and inhibition in
brain networks, leading to epileptogenesis. The alterations
in neurotransmitters and receptor expression may provide
targets for drug therapy (for a review, see ref. [9]). The find-
ing of overexpression of multi-drug transporters in patients
with brain tumors further suggests that tumor-related epi-
lepsy and SE require a specific therapeutic strategy [9].
Until now, no particular anticonvulsant has been shown to
be superior to others in treating adults with brain tumor-
related epilepsy [10].
These pathophysiological and pharmacological data
point towards a specific mechanism underlying tumor-
related SE, and suggest that the efficacy of available an-
ticonvulsants may differ between tumor-related SE and
SE due to other causes. However, in the current clinical
situation, SE is now treated uniformly regardless of
underlying cause. If tumor-related SE is truly characterized
by a specific underlying mechanism and sensitivity to anti-
convulsants, this might be reflected in a different clinical
outcome between tumor-related SE and SE due to other
causes.
To study potential differences between tumor-related
SE and SE due to other causes, we conducted a systematic
review of the literature and a meta-analysis. We aimed to
answer the following questions:
1. Does outcome in tumor-related SE differ from SE
due to other causes in terms of short-term mortality,
long-term morbidity (neurological deficits lasting
beyond the initial post-ictal period) and duration
of SE?
2. Does the efficacy of particular treatments differ
between tumor-related SE and SE due to other causes?
Methods
We performed two systematic searches in the PubMed
database. The results have been updated until January 12,
2013. No ethical committee approval was deemed neces-
sary for this literature review and meta-analysis.
Outcome of status epilepticus
For the first search, the term status epilepticus was com-
bined with outcome, mortality, morbidity, fatality, progno-
sis, coma, death, incidence, prevalence and epidemiology.
For a paper to be included in this literature review, status
epilepticus had to be defined as a single continuous seiz-
ure or a series of epileptic seizures with clouded con-
sciousness between ictal events; although most studies
used a minimum duration of 30 minutes in the definition
(in accordance with traditional guidelines), we did not use
this as an inclusion criterion since modern data and
guidelines use less stringent time criteria [6]. We limitedthe search to human studies on adults written in English,
Dutch or Turkish. We excluded review articles, case re-
ports and treatment protocols. Full text screening and
reviewing of the residual studies was conducted. We in-
cluded studies on generalized and focal SE (or both), but
excluded studies that focused on specific subgroups of SE
such as refractory SE, elderly patients only or critically ill
patients. To be included, a study had to have more than 5
tumor patients in the study group. Also, information on
one or more of the following outcomes had to be available:
short-term mortality, long-term morbidity and duration of
SE. The screening and selection of papers from the original
search was performed by one author (YA) and reviewed by
the last author (TJS).
We defined mortality as short-term mortality, and we
included data on 30-day mortality, case fatality or mortal-
ity at discharge. Long-term morbidity was defined as the
occurrence of new neurological deficits that lasted beyond
the regular post-ictal period. To be included, data had to
be available on (a) either the ‘back to baseline’-percent-
ages, or – conversely – the percentages of patients who
had worsened clinically after SE, and (b) mortality. For in-
clusion in the analysis on duration of SE, data had to be
available on the mean SE duration (in minutes or hours).
For all the outcomes, we extracted separate data for
tumor-related SE versus SE due to other causes.
Within the subgroup of SE due to causes other than
tumors, the subgroup of patients with hypoxic/anoxic en-
cephalopathy (HAE) after cardiopulmonary resuscitation
represents a specific subgroup, in which the occurrence of
SE itself is associated with a very poor prognosis [11]. In
these cases, the mortality is thought to be the conse-
quence of the disease itself (HAE) rather than of the SE.
To exclude an effect of such HAE-associated mortality on
the outcomes, the outcome analyses were repeated after
exclusion of cases with HAE-associated SE.
Authors were contacted by email if a study had miss-
ing or incomplete information.
Based on the data from the separate studies, we calcu-
lated the total number of patients with tumor-related SE
and patients with SE due to another cause. We then cal-
culated total mortality and morbidity and the median
duration of SE for both groups. From these grouped
data, we calculated the weighted averages for all out-
comes, and expressed the difference between patient
groups as relative risk (RR) and 95% confidence interval
(95%-CI) for mortality and morbidity. For comparison
of SE duration between groups, we used the Mann-
Whitney test.
Anticonvulsant therapy
An extensive search query was applied to find studies on
the efficacy of anticonvulsant therapy in treating tumor-
related SE, rather than SE treatment in general. The
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plied the same limits as in the search on outcome. Treat-
ment protocols and reviews were excluded. This method
resulted in a very small number of studies. Therefore, we
chose to include all studies with more than one patient
with tumor-related SE. The data presentation is descrip-
tive in nature, since no formal quantitative analysis (meta-
analysis) could be performed.Results
The results of the search concerning outcome of SE are
given in Figure 1. Of the fourteen studies that met the
criteria, important data on the outcome measures were
missing in nine studies. We tried to obtain these non-
reported data through the corresponding author. If this
did not result in additional data we categorized the study
as ‘no analyzable data’, which was the case in three stud-
ies that met the initial inclusion criteria for the outcome
mortality, leaving nine analyzable studies. Of these nine
studies with valid mortality data, one study did not pro-
vide separate data on cases of HAE; consequently, eight
studies were included in the analysis with exclusion of
HAE cases.Figure 1 Flowchart of the search for the prognosis of tumor-related s
studies had data for 2 outcomes. SE = status epilepticus, RSE = refractory staFor the analysis on long-term morbidity, we did not leave
out any study. For the analysis on SE duration, six studies
only mentioned the median duration or range, in which
case we had to categorize them as ‘no analyzable data’.Short-term mortality
The data from the nine studies that we included can be
found in Table 1. Short-term mortality in tumor-related
SE was higher than in SE due to other causes (weighted
average 17.2% versus 11.3%, RR 1.53, 95%-CI 1.24-1.90).
After exclusion of cases of HAE, this difference increased
(tumor-related SE 17.2% versus non-tumor-related SE
6.5%; RR 2.66, 95%-CI 2.14 – 3.31).Long-term morbidity
Only one study (Scholtes et al.) [17] made a distinction
between morbidity for tumor-related SE and other causes
of SE. All other studies only mentioned the morbidity in
the total group. In the study by Scholtes et al., 33.3% of
the patients in the tumor group were clinically worse than
before the SE, 50% recovered and 16.7% died. For the
group of patients with SE from other causes, the numbers
were 15.2%, 70.1% and 14.7% respectively (RR for long-tatus epilepticus versus status epilepticus by other causes. *Some
tus epilepticus.
Table 1 Mortality in tumor-related status epilepticus versus status epilepticus due to another cause










Type of study Setting
Amare [12] 119 13 23.1% 19.8% 18.4% Retrospective Tertiary hospital
Cavaliere [13]* 35 34 23.0% 0% 0% Retrospective University hospital
Chen [14]**# 220 17 11.8% 15.3% n/a# Prospective University hospital
DeLorenzo [7] 137 10 30.0% 36.2% 31.4% Prospective Population based
Li [15] 203 15 13.3% 16.0% 16.1% Retrospective University hospital
Rossetti [16] 96 14 21.4% 14.6% 14.6% Prospective University hospital
Scholtes [17] 236 12 16.7% 14.7% 14.8% Retrospective Hospitals and epilepsy
centers
Towne [18] 253 11 36.0% 22.7% 17.5% Retrospective Hospital
Wu [19] 15601 291 15.5% 10.7% 5.8% Retrospective Population based
Total 16900 417
Weighted averages 17.2% 11.3% 6.5%
*This study only included tumor patients; one patient had a systemic tumor without brain-metastasis. **Brain neoplasm and developmental malformation were in
the same group. Separate data could not be obtained. #No separate data on hypoxic/anoxic encephalopathy were given. HAE = hypoxic/anoxic encephalopathy.
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95%-CI 0.92-3.05).
Duration
We found three studies with data on SE duration, of
which only one study specified the duration for tumor-
related SE [20]. Mean duration of the SE in the tumor
group was 152.9 (standard error 43.0, median 70.0)
minutes versus 174.1 (standard error 18.6, median 85.0)
minutes in SE due to other causes.
Anticonvulsant therapy
The search on anticonvulsant therapy in patients with
tumor-related SE resulted in three articles with more
than one tumor-related SE (see Additional file 2). Given
this paucity of data and the lack of prospective compara-
tive series, it was not possible to formally compare data
between tumor-related and non-tumor-related SE. The
available descriptive data can be found in Additional file 3.
Discussion
In this systematic search and meta-analysis on differ-
ences in outcome between status epilepticus (SE) due to
a brain tumor and SE due to other causes, we found a
significantly higher mortality for tumor-related SE (17.3%
versus 11.2%, RR 1.53, 95%-CI 1.24-1.90). This excess
mortality in tumor-related SE was even more pronounced
after exclusion of patients with hypoxic-ischemic enceph-
alopathy from the non-tumor group (17.2% versus 6.5%,
RR 2.66, 95%-CI 2.14 – 3.31). Available data on long-term
morbidity and duration of SE were insufficient to draw
any definite conclusions. Regarding long-term morbidity,
the study by Scholtes et al. [17] shows a non-significant
increase in morbidity in tumor-related SE (33.3% versus
15.2% in SE due to other causes). As for the duration ofthe SE, Legriel et al. [20] found a shorter duration in
tumor-related SE (152.9 versus 174.1 minutes).
There is a substantial heterogeneity in mortality data,
which increases the risk of bias; of note, the large-scale
study by Wu et al. [19] largely determined our findings
on mortality, since it provides 92% of the patients in this
analysis. Another limitation of our analysis was that
most of the studies initially included were mainly about
SE in general (with the study by Cavaliere et al. [13] as
an exception), and separate data for tumor patients and
non-tumor patients were not available; for most of the
studies, these specific data could no longer be retrieved
from the authors. These unobtainable data limited com-
parative analysis for the outcome measures long-term
morbidity and SE duration.
The reviewed studies do not provide data on the role
of different types of brain tumors. This limits the inter-
pretation of the data, since previous literature has shown
that different brain tumors greatly differ in epileptogeni-
city [1]. Also, the preclinical and translational data that
point towards a distinct pathophysiological mechanism
of epilepsy and SE in patients with brain tumors, were
mostly derived from patients with gangliogliomas and
other glial tumors [9]. Future studies on tumor-related
SE should report separately for the different types of brain
tumors, in order to elucidate whether our findings on
tumor-related SE apply for all brain tumors, or whether
they are specific to certain tumor types. In addition, further
studies should investigate whether the occurrence and out-
come of tumor-related SE is dependent on (previous or
current) anti-tumor-treatment such as radio- and chemo-
therapy, since several anti-tumor treatments are associated
with reduction of epilepsy burden [1].
It is uncertain whether the increased mortality in
tumor-related SE is the consequence of the SE itself
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tumor or the possibility of selection of certain – prog-
nostically unfavorable – subgroups in the included stud-
ies may (also) explain excess mortality.
The few articles on the efficacy of anticonvulsant(s) in
treating tumor-related SE versus SE due to other causes
were too heterogeneous and of insufficient quality to
permit any formal analysis. This finding supports the no-
tion that tumor-related SE is not yet considered a separ-
ate clinical entity.
Conclusion
Pooled data from observational, mostly retrospective, stud-
ies show that tumor-related status epilepticus is associated
with a statistically significant increase in mortality com-
pared to status epilepticus by other causes. Available low-
quality data suggest a higher rate of long-term morbidity
and shorter duration of status epilepticus in tumor-related
status epilepticus than in status epilepticus by other causes.
However, data interpretation is hindered by the heterogen-
eity between studies and the lack of data on tumor sub-
types and possible underlying tumor progression.
Based on the available data, no conclusion can be for-
mulated on the efficacy of particular anticonvulsants in
tumor-related SE versus SE due to other causes.
Further research is needed to provide more data about
mortality, long-term morbidity, duration of the status epi-
lepticus, and efficacy of anticonvulsants in tumor-related
status epilepticus. Future studies on outcome of SE should
treat tumor-related SE as a separate entity.
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